PortfoliosLab logo
Allarity Therapeutics, Inc. (ALLR)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN

US0167441049

CUSIP

016744104

IPO Date

Dec 21, 2021

Highlights

Market Cap

$17.42M

EPS (TTM)

-$15.65

Gross Profit (TTM)

-$1.00K

EBITDA (TTM)

-$20.89M

Year Range

$0.61 - $22.20

Target Price

$5.00

Short %

8.32%

Short Ratio

1.05

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Performance

Performance Chart


Loading data...

Returns By Period

Allarity Therapeutics, Inc. (ALLR) returned -11.11% year-to-date (YTD) and -95.64% over the past 12 months.


ALLR

YTD

-11.11%

1M

42.23%

6M

-28.77%

1Y

-95.64%

5Y*

N/A

10Y*

N/A

^GSPC (Benchmark)

YTD

0.08%

1M

9.75%

6M

-1.63%

1Y

12.74%

5Y*

15.66%

10Y*

10.77%

*Annualized

Monthly Returns

The table below presents the monthly returns of ALLR, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2025-4.27%-28.69%17.30%28.08%-13.33%-11.11%
2024-21.14%-11.04%-22.12%-78.91%-51.50%-65.44%-14.51%-0.27%-61.25%-33.65%-21.43%6.36%-99.65%
2023-14.91%-26.00%-74.05%-73.81%-40.11%-37.38%-61.52%-27.17%-59.62%-25.44%-0.69%-0.37%-99.87%
20220.00%0.00%0.00%0.00%-0.00%0.00%-0.00%-1.72%-5.98%-49.08%-19.84%-34.57%-75.32%
20210.00%0.00%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of ALLR is 7, meaning it’s performing worse than 93% of other stocks on our website when it comes to balancing risk and reward. Below is a breakdown of how it compares using common performance measures.


The Risk-Adjusted Performance Rank of ALLR is 77
Overall Rank
The Sharpe Ratio Rank of ALLR is 99
Sharpe Ratio Rank
The Sortino Ratio Rank of ALLR is 11
Sortino Ratio Rank
The Omega Ratio Rank of ALLR is 22
Omega Ratio Rank
The Calmar Ratio Rank of ALLR is 11
Calmar Ratio Rank
The Martin Ratio Rank of ALLR is 2020
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Allarity Therapeutics, Inc. (ALLR) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


The Sharpe ratio helps investors understand how much return they're getting for the level of risk taken. A higher Sharpe ratio indicates better risk-adjusted performance, meaning more reward for each unit of risk.

Allarity Therapeutics, Inc. Sharpe ratios as of May 14, 2025 (values are recalculated daily):

  • 1-Year: -0.81
  • All Time: -0.86

These values reflect how efficiently the investment has delivered returns relative to its volatility over different time periods. All figures are annualized and based on daily total returns (including price changes and dividends).

The chart below shows the rolling Sharpe ratio of Allarity Therapeutics, Inc. compared to the selected benchmark. This view highlights how the investment's risk-adjusted performance has changed over time. For deeper analysis or to customize the calculation, use the Sharpe ratio tool.


Loading data...

Dividends

Dividend History


Allarity Therapeutics, Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


Loading data...

Worst Drawdowns

The table below displays the maximum drawdowns of the Allarity Therapeutics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Allarity Therapeutics, Inc. was 100.00%, occurring on Apr 9, 2025. The portfolio has not yet recovered.

The current Allarity Therapeutics, Inc. drawdown is 100.00%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-100%Sep 29, 2022634Apr 9, 2025
-12.64%May 12, 202280Sep 6, 20222Sep 8, 202282
-8.44%Sep 20, 20225Sep 26, 20222Sep 28, 20227
-2.55%Sep 9, 20222Sep 12, 20221Sep 13, 20223
-1.72%Sep 14, 20221Sep 14, 20221Sep 15, 20222

Volatility

Volatility Chart

The chart below shows the rolling one-month volatility.


Loading data...

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Allarity Therapeutics, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.


Annual
Quarterly

0.0

Earnings Per Share

The chart presents the Earnings Per Share (EPS) performance of Allarity Therapeutics, Inc., comparing actual results with analytics estimates. The company has exceeded analyst expectations for EPS in the past quarter, achieving a 79.2% positive surprise.


-1,000,000.00-800,000.00-600,000.00-400,000.00-200,000.000.0020212022202320242025
-1.02
-8.40
Actual
Estimate

Valuation

The Valuation section provides an overview of how Allarity Therapeutics, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.


PS Ratio

This chart shows the Price-to-Sales (P/S) ratio for ALLR relative to other companies in the Biotechnology industry. Currently, ALLR has a P/S ratio of 0.0. This P/S ratio is low compared to the industry average. It may indicate that the stock is undervalued relative to its revenue, or that the market expects slower growth or lower margins.

PB Ratio

The chart illustrates the Price-to-Book (P/B) ratio for ALLR in comparison with other companies in the Biotechnology industry. Currently, ALLR has a P/B value of 1.5. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items